Maintaining remission in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis who have kept their autoantibodies in check after at least 2 years on rituximab therapy has ...

A new guideline from Kidney Disease: Improving Global Outcomes (KDIGO) updates recommendations on the management of antineutrophilic cytoplasmic antibody (ANCA)–associated vasculitis (AAV) to address ...

Despite the frequency of coronary artery calcification among patients with antineutrophil cytoplasmic antibody-associated vasculitis, only 25% were using statins. A significant percentage of patients ...

AAV is diagnosed based on symptoms listed above and the following laboratory tests. Based on which organs that may not be functioning well, imaging or biopsy may be performed. ANCA test, which is a ...

(RTTNews) - Biopharmaceutical company ChemoCentryx, Inc. (CCXI) announced Friday that the U.S. Food and Drug Administration (FDA) has approved Tavneos (avacopan), as an adjunctive treatment of adult ...

Please provide your email address to receive an email when new articles are posted on . Targeting the complement pathway using a C5a agonist may be a “game changer” in anti-neutrophil cytoplasmic ...

The guideline recommends that glucocorticoids in combination with rituximab or cyclophosphamide be used as initial treatment for new-onset ANCA-associated vasculitis. The Kidney Disease: Improving ...

Please provide your email address to receive an email when new articles are posted on . Despite an ever-growing array of potential candidate biomarkers for antineutrophil cytoplasmic ...

An investigational C5a receptor inhibitor, avacopan, was effective as a steroid-sparing induction treatment for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis in a phase III trial ...

The Committee vote split 9-9 on the first question, whether the efficacy data support approval of avacopan for the treatment of adult patients with AAV (granulomatosis with polyangiitis (GPA) and ...